

06-29-05

JTW 1614  
CASE ON/4-32375A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 483 669 131 45

Express Mail Label Number

JUNE 27 2005

Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

PRESCOTT ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/02028

FILED: 27 FEBRUARY 2003

U.S. APPLICATION NO: 10/505,398 ✓

35 USC §371 DATE: 29 APRIL 2005

FOR: N(5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL)-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE COATED STENTS

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/02028, copies are not enclosed herewith.


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

Date: 6/29/05

  
\_\_\_\_\_  
Oona A. Jackson  
Attorney for Applicants  
Reg. No. 48,152

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	AM 99 03854	1/28/99	WO			<input type="checkbox"/> <input type="checkbox"/>
	AN 00 09098	2/24/00	WO			<input type="checkbox"/> <input type="checkbox"/>
	AO					<input type="checkbox"/> <input type="checkbox"/>
	AP					<input type="checkbox"/> <input type="checkbox"/>
	AQ					<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Myllarniemi et al., "Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo," Cardiovascular Drugs and Therapy, Vol. 13(2), pp. 159-168 (1999)
AS	Showalter et al., "Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and SRC family tyrosine kinases," Pharmacology and Therapeutics, Vol. 76(1-3), pp. 55-71 (1997)
AT	

EXAMINER /Marcos Sznajdman/

DATE CONSIDERED

02/20/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.